Bloorview Research Institute, Holland Bloorview Kids Rehabilitation Hospital, 150 Kilgour Road, Toronto, M4G 1R8 ON Canada.
Clinical Research Services, Hospital for Sick Children, Dalla Lana School of Public Health, University of Toronto, Toronto, Canada.
Mol Autism. 2015 Mar 21;6:18. doi: 10.1186/s13229-015-0010-7. eCollection 2015.
Autism spectrum disorder (ASD) is a neurodevelopmental disorder affecting more than 1% of children. It is characterized by social communication deficits and repetitive behaviors/restricted interests. In the absence of any medications known to improve core symptom domains, parents often use complementary alternative treatments, including omega-3 fatty acid supplements.
We conducted a 6-month, randomized, placebo controlled trial of omega-3 fatty acid supplements (1.5 g) vs placebo in children 2 to 5 years of age with ASD. Primary outcome measures included the autism composite score of the Pervasive Developmental Disorders Behavioral Inventory (PDDBI) and the externalizing problems score of the Behavior Assessment System for Children (BASC-2). Secondary outcome measures included clinical global improvement (Clinical Global Impression-Improvement (CGI-I)), adaptive function (Vineland Adaptive Behavior Scale (VABS-II)), and language gains (Preschool Language Scale (PLS-4)), as well as safety. Exploratory analysis investigated potential correlations between changes in cytokine profiles and treatment response.
Thirty-eight participants were randomized in a 1:1 fashion. There was no significant difference between groups on the 0- to 24-week change in PDDBI autism composite scores (p = 0.5). There was a significant group by week interaction on the BASC-2 externalizing problem score, with participants randomized to the treatment group demonstrating worsening scores (p = 0.02). There was no statistically significant week by group effect on either adaptive function (p = 0.09) or language (p = 0.6). Omega-3s were relatively well tolerated. Changes in cytokines during the study did not significantly correlate with treatment response.
This study does not support high dose supplementation of omega-3 fatty acids in young children with ASD.
Clinicaltrials.gov NCT01248728. Registered 22 November 2010.
自闭症谱系障碍(ASD)是一种影响超过 1%儿童的神经发育障碍。其特征是社交沟通障碍和重复行为/受限兴趣。在没有任何已知药物可以改善核心症状领域的情况下,父母经常使用补充替代疗法,包括ω-3 脂肪酸补充剂。
我们进行了一项为期 6 个月、随机、安慰剂对照的ω-3 脂肪酸补充剂(1.5g)与安慰剂治疗 2 至 5 岁 ASD 儿童的试验。主要结局指标包括广泛性发育障碍行为评定量表(PDDBI)的自闭症综合评分和儿童行为评估系统(BASC-2)的外化问题评分。次要结局指标包括临床总体改善(临床总体印象-改善(CGI-I))、适应功能(适应行为量表第二版(VABS-II))和语言增益(学前语言量表(PLS-4)),以及安全性。探索性分析研究了细胞因子谱变化与治疗反应之间的潜在相关性。
38 名参与者以 1:1 的比例随机分组。在 PDDBI 自闭症综合评分的 0 至 24 周变化方面,两组之间无显著差异(p=0.5)。BASC-2 外化问题评分存在显著的组间-周交互作用,随机分组至治疗组的参与者表现出评分恶化(p=0.02)。在适应功能(p=0.09)或语言(p=0.6)方面,两组之间在任何一周都没有统计学上显著的影响。ω-3 脂肪酸相对耐受良好。研究期间细胞因子的变化与治疗反应无显著相关性。
本研究不支持在 ASD 幼儿中补充高剂量的ω-3 脂肪酸。
Clinicaltrials.gov NCT01248728。于 2010 年 11 月 22 日注册。